ArticleCancer management and research2022

Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels.

Norikazu Masuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.